Welcome to Oligovax !

Oligovax is a biopharmaceutical company focused on developing innovative therapies for cancer.

The company’s leads molecule, Litenimod, is potent agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.

Such a mechanism of action provides the potential to use Litenimod either alone, or as a vaccine adjuvant, or combined to monocolonal antibodies.

Oligovax has successfully completed several clinical trials in cancer, and is conducting pre-clinical studies using Litenimod as an adjuvant in vaccine and/or immunotherapeutic approaches.